It is worthy to note that in human, genetic variants of PPARγ (C161T, Pro12Ala) or dominant-negative mutations are specifically associated with NAFLD and progression of NAFLD towards inflammation and fibrosis [36–41]. This evidence concerns the gene PPARG and metabolic dysfunction-associated steatotic liver disease.